Table 4 Treatment-emergent adverse events summary

From: Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial

 

Lerociclib + Fulvestrant (N = 137)

Placebo + Fulvestrant (N = 138)

Any grade, n (%)

135 (98.5%)

111 (80.4%)

≥Grade 3, n (%)

79 (57.7%)

21 (15.2%)

Serious AE, n (%)

8 (5.8%)

11 (8.0%)

AE leading to treatment discontinuation, n (%)

1 (0.7%)

0

AE leading to death, n (%)

1 (0.7%)a

0

  1. AE adverse event.
  2. aNot treatment related.
Back to article page